TUCSON, Ariz., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Today HTG Molecular Diagnostics, Inc. announced the availability of the HTG EdgeSeq Oncology Biomarker panel for profiling the expression of over 2,500 oncology related biomarkers. Automated on the HTG EdgeSeq system, HTG EdgeSeq Oncology Biomarker Panel couples HTG's proprietary nuclease protection chemistry with next-generation-sequencing (NGS).
"After extensive market analysis this panel was designed to offer a comprehensive set of biomarkers for profiling tumor tissues, analyzing cancer pathways and identifying new biomarkers across both solid tumors and hematolymphoid neoplasms," commented Chris Roberts, HTG's Vice President of Marketing and Medical Innovation.
"The Oncology Biomarker Panel is our second major panel to be optimized on the HTG EdgeSeq system providing highly multiplexed information in a simple to use automation platform from a single section of tissue," commented TJ Johnson, HTG's Chief Executive Officer. "We continue to believe that the combination of HTG's extraction free sample and library preparation chemistry automated on the HTG Edge system with NGS quantitation is providing customers with a powerful new capability," Mr. Johnson added.
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics' mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing.Additional information is available at www.htgmolecular.com.
CONTACT: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: email@example.com TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: firstname.lastname@example.org
Source:HTG Molecular Diagnostics